As the most widely researched childhood disorder, ADHD treatments and programs remain at the forefront of pediatric and psychiatric professionals, in addition to being designed for school educators and parents. In young children, usually under the age of 12, parents often find the management of ADHD with prescribed oral medications difficult as many children simply cannot, and will not, swallow a pill. A breakthrough in the treatment of pediatric ADHD, the development of an ADHD patch, Daytrana, allows for treatment in small. children. An understanding of the concept behind the patch, side effects and contraindications will enable parents to make informed care decisions. about a child with ADHD
Daytrana, an ADHD patch manufactured by Noven Pharmaceuticals, is the size of a credit card. Offering a nine-hour continuous and sustained release of methylphenidate, the ADHD patch, Daytrana, is considered an ideal alternative to traditional oral pill forms of methylphenidate, such as Ritalin and Concerta. Targeted primarily at children ages six to 12, the patch is expected to treat approximately 15 percent of the pediatric ADHD population. Placed on the child’s hip, the disadvantage of using a suture is the child’s ability to remove the suture at any time. However, with proper training, most children will find that the therapeutic results are significant enough to result in the patch not being removed.
It was previously rejected by the FDA in 2003 under a 12-hour suspended patch release, the new patch, under a nine-hour sustained release, was approved by FDA in 2006. Preliminary studies showing parts among conditions, insomnia and significant weight damage, the FDA has approved a modified version of the patch that has been shown to significantly reduce side effects as previously demonstrated. Of secondary concern is the indication of the development of skin rash in and around Daytrana. repair room in the hips. Although rare, rash has been shown to be a significant cause of concern. The adHD panel reviewing the patch for a second approval review recommended that the patch be used only as a second line of therapy in the event that oral medications are not well administered or used to resolve ADHD symptoms.
The use of Daytran, an ADHD patch, is contraindicated in child anxiety, glaucoma and those suffering from severe stress. agitation In children currently being treated for depression, the use of Daytrana may also be contraindicated and should be done with a pediatrician or psychiatrist prescribing an ADHD patch. Dosing is recommended in a patch of 30 mg that is removed immediately after nine hours of administration which provides additional care regarding administration during the period of the school day.
For children suffering from ADHD symptoms, the use of methylphenidate provides significant results in alleviating ADHD symptoms, while social correction; emotional and academic performance. For children unable to use oral medications, the use of Daytrana, an ADHD patch, can be considered as a second line of therapy. For more information, contact your child’s pediatrician about the uneven use of Daytrana.
